摘要
目的:观察中药复方联合FOLFOX4方案治疗晚期胃癌的临床疗效。方法:将60例晚期胃癌患者按入院顺序分为治疗组和对照组各30例。对照组患者采用FOLFOX4方案治疗,2周为1个治疗周期,共治疗8个周期。治疗组化疗方案同对照组,并自化疗开始持续服用中药复方4个月。治疗结束后,评价两组临床疗效,并对两组治疗前后的中医症状评分、生活质量评分[包括Karnofsky行为状况(KPS)评分和EORTC QLQ-C30生命质量量表评分]、肿瘤标志物水平进行比较。结果:①治疗后,两组临床疗效比较,差异无统计学意义(P>0.05)。②治疗后,治疗组患者胃脘疼痛、纳差、乏力症状评分较治疗前明显降低,胃脘疼痛、纳差、乏力、大便异常症状评分低于对照组,且治疗组中医症状改善情况明显优于对照组,差异均有统计学意义(P<0.05或P<0.01)。③治疗组患者治疗后的KPS评分较治疗前明显升高,且高于对照组患者治疗后的KPS评分,差异均有统计学意义(P<0.01);治疗后,治疗组患者EORTC QLQ-C30生命质量量表中部分项目的评分较治疗前明显改善,且改善程度优于对照组,差异有统计学意义(P<0.05或P<0.01)。④治疗后,治疗组患者癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、胃蛋白酶原Ⅰ(PGⅠ)、糖类抗原72-4(CA72-4)水平较治疗前明显下降,CEA、CAl9-9、PGⅠ水平低于对照组,差异均有统计学意义(P<0.05或P<0.01)。结论:中药复方联合FOLFOX4方案治疗晚期胃癌在提高患者生活质量、缓解临床症状、降低肿瘤标记物水平方面均优于单纯FOLFOX4方案化疗。
Objective:To observe the clinical curative efficacy of Chinese herbal compound combined with FOLFOX4 regimen in the treatment of advanced gastric cancer.Methods:A total of 60 patients with advanced gastric cancer were divided into treatment group and control group according to the time of admission,with 30 patients in each group.Patients in the control group were treated with FOLFOX4 regimen only.One treatment course lasted for 2 weeks and the patients were treated for eight courses.Patients in the treatment group were treated with the same chemotherapy regimen,and since the beginning of chemotherapy,they took Chinese herbal compound continuously for 4 months.After treatment,the curative efficacy of the two groups was evaluated.The traditional Chinese medicine(TCM) symptom scores,Karnofsky performance status(KPS) score,EORTC QLQ-C30 life quality scale score and tumor marker levels of the two groups were compared before and after treatment. Results:①After treatment,the difference of clinical curative efficacy between the two groups was not statistically significant(P>0.05). ②After treatment,the scores of epigastric pain,poor appetite and lack of strength of patients in the treatment group were significantly lower than those before treatment,and the scores of epigastric pain,poor appetite,lack of strength and abnormal stool of patients in the treatment group were lower than those in the control group. Besides,the improvement of TCM symptom of the treatment group was better than that of the control group. All the above differences were statistically significant(P<0.05 or P<0.01). ③After treatment,the KPS score of the treatment group was higher than that before treatment,as well as than that of the control group. The differences were statistically significant(P<0.01). Some scores in the EORTC QLQ-C30 life quality scale of the treatment group were improved and the improvement was better than that of the control group.The differences were statistically significant(P<0.05 or P<0.01). ④After treatment,the levels
作者
毛毛
孙永浩
焦宁
卢言平
吴素芹
MAO Mao;SUN Yonghao;JIAO Ning;LU Yanping(Zibo Hospital of Traditional Chinese Medicine,Zibo 255300,China)
出处
《山东中医杂志》
2020年第10期1075-1079,共5页
Shandong Journal of Traditional Chinese Medicine
